NACCME: Health Alerts

Home Testimonials Joint Sponsorship Links Help My Account Contact Us

Advances in Neuromuscular Blockade: Developments in Monitoring and Reversal (CME)

Patient-Centered Approaches to the Diagnosis and Management of Atrial Fibrillation (CME,CNE,CPE)

Immunization Rates and Healthcare Utilization – Improving Awareness and Access in Special Populations (CME,CNE,CPE)

Biologic Therapy in the Management of Psoriasis: A Perspective for Managed Markets (CME,CPE)

Beta Blockade in Cardiovascular Disease: Emerging Therapies and HEDIS® Measures (CME,CPE)

Rheumatoid Arthritis in the Elderly- A Distinct Clinical Entity (CME)

Symposium on Advanced Wound Care (SAWC) Adds Fall Meeting

View Health Alerts

About Us
Contact Us
Privacy Policy
CME Standards and Policies
Copyright Policy
Disclosure

Health Alerts

Participants of CME/CE activities via this site should be aware of the following:

FDA Warns of Heart Risks with Schizophrenia Drug Haldol®
US regulators said on Monday that Johnson & Johnson added new warnings to its schizophrenia drug, Haldol® (haloperidol)... (Posted September 20, 2007)

Cephalon Warns Doctors about Deaths Linked to Pain Drug FENTORA®
Cephalon, Inc. today communicated with healthcare professionals to clarify the appropriate patient selection, dosing and administration for FENTORA®... (Posted September 14, 2007)

Zelnorm® to be Made Available to US Patients under Restricted Access Program
In cooperation with the US FDA, Novartis has established a restricted access program for Zelnorm®... (Posted July 27, 2007)

Takeda Revises ACTOS® Prescribing Label
Takeda Pharmaceuticals North America, Inc. (TPNA) today announced that the company will revise warnings related to... (Posted June 6, 2007)